Update on requirement to obtain certain specialty drugs from CVS Specialty Pharmacy effective January 1, 2022

As we previously communicated, Anthem implemented a policy requiring hospitals to acquire certain select specialty pharmacy medications administered in the hospital outpatient setting through CVS Specialty Pharmacy.

 

This update is to advise of the following changes:

 

Effective for dates of service on and after January 1, 2022, the following specialty pharmacy medications will be added to the Designated Medical Specialty Pharmacy drug list and must be procured from CVS Specialty Pharmacy pursuant to the policy.

 

HCPCS	Description	Brand name
J1554	Injection, immune globulin (asceniv), 500 mg	Asceniv
J7204	Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu	Esperoct
J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.	Jivi
J7212	Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram	Sevenfact
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	Darzalex Faspro

 

The Designated Medical Specialty Pharmacy drug list may be updated periodically by Anthem.

 

To access the current Designated Medical Specialty Pharmacy Drug List, visit anthem.com, select Providers, select the state Connecticut (top right of page), select Forms and Guides (under the Provider Resources column). Scroll down and select Pharmacy in the Category drop down. The Designated Medical Specialty Pharmacy drug list may be updated periodically by Anthem.

 

 

If you have questions or would like to discuss the terms and conditions for providing certain specialty medications, please contact your Anthem Contract Manager. Thank you for your continued participation in the Anthem networks and the services you provide to our members.

 

1348-1021-PN-CT